Drug Discovery & Pharmaceuticals

RSS

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Intabio, Inc., announced today that it has entered into a collaboration with Bruker to accelerate integration of Intabio's Blaze™ solution with Bruker's high resolution mass spectrometers.

From Bruker Life Sciences Mass Spectrometry 14 Jun 2018

Sharks could inspire new type of surface that would attack harmful bacteria

Sharks are often the subject of TV specials or news stories focusing on their attacks on humans. But scientists are finding that sharks could inspire a new type of surface that would attack bacteria, helping humans instead of hurting them.

14 Jun 2018

Scientists discover vaccine that may rapidly fight cholera-causing bacteria

A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest.

14 Jun 2018

Unique project to develop fully-automated technology for faster and effective drug discovery

A unique project to develop technology to drive fast and effective drug discovery was announced today by Business Secretary Greg Clark. Based at the Rosalind Franklin Institute in Harwell, Oxfordshire, this new project will pioneer fully-automated hands-free molecular discovery to produce new drugs up to ten times faster and transform the UK’s pharmaceutical industry.

13 Jun 2018

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

AbCellera Biologics Inc. today announced the successful completion of the first phase of its collaboration with Denali Therapeutics Inc.

12 Jun 2018

Combination of antibodies shown to cause rheumatoid arthritis

Researchers have shown that severe inflammation and joint damage in rheumatoid arthritis (RA) is primarily caused by a combination of different antibodies.

12 Jun 2018

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five undisclosed infectious disease pathogens.

11 Jun 2018

Research drug may one day be novel treatment for systemic inflammatory response syndrome

When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.

11 Jun 2018

International experts agree on need for human-relevant research to improve drug discovery

The average pre-approval cost of research and development for a successful drug is estimated to be US$2.6 billion and the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950.

8 Jun 2018

Neem Biotech present biofilm disruptor at BIO Boston 2018, to minimise antimicrobial resistance

Neem Biotech, a Wales based pharmaceutical biotech working in the field of novel antimicrobial research and development will present details of the company’s approach to minimising antimicrobial resistance through biofilm disruption at BIO Boston 2018.

From Neem Biotech 7 Jun 2018

Microbiotica collaborates with Genentech to develop drugs for IBD

Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.

6 Jun 2018

IONTAS collaborates with LG Chem to discover antibodies for treating cancer

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers.

5 Jun 2018

Study identifies four tumor survival strategies in childhood cancer

Researchers have identified four main trajectories for the development of childhood cancer, two of which have been linked to disease relapse.

5 Jun 2018

Altering bacteria’s genetic code may pave way for long-lasting drugs, shows study

By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases.

5 Jun 2018

Researchers use nanoparticles to predict heavy wound scarring

Researchers have developed a new way of seeing heavy wound scars as they form, using nanoparticles that enable early intervention by doctors.

4 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Drug Discovery & Pharmaceuticals

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Sharks could inspire new type of surface that would attack harmful bacteria

Scientists discover vaccine that may rapidly fight cholera-causing bacteria

Unique project to develop fully-automated technology for faster and effective drug discovery

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

Combination of antibodies shown to cause rheumatoid arthritis

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

Research drug may one day be novel treatment for systemic inflammatory response syndrome

International experts agree on need for human-relevant research to improve drug discovery

Neem Biotech present biofilm disruptor at BIO Boston 2018, to minimise antimicrobial resistance

Microbiotica collaborates with Genentech to develop drugs for IBD

IONTAS collaborates with LG Chem to discover antibodies for treating cancer

Study identifies four tumor survival strategies in childhood cancer

Altering bacteria’s genetic code may pave way for long-lasting drugs, shows study

Researchers use nanoparticles to predict heavy wound scarring

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

UK scientists 3D-print the first human corneas

Discovering Antibodies with Universal Specificity

Study shows blood stem cells compensate for immune cell deficiencies

Researchers uncover the cause of rheumatoid arthritis

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest Life Science News